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Objectives We investigated the clinical utility of B-type natriuretic peptide (BNP) assay in stable outpatients with non-
ischemic dilated cardiomyopathy (NICM) after decompensated heart failure (HF).
Background Patients with NICM admitted for decompensated HF frequently experience sudden death or redecompensation
after hospital discharge. The prognostic value of BNP during hospitalization has been demonstrated. However,
clinical utility of BNP in stable outpatient setting has been poorly investigated.
Methods Eighty-three NICM outpatients who were clinically stable in New York Heart Association functional class 1 to 2 for 6
months after discharge for decompensated HF were enrolled, and then followed for an additional 18 months.
The main end point was first readmission for decompensated HF or death. B-type natriuretic peptide levels were measured
at 3-month intervals from discharge to enrollment, and echocardiographic dimensions at discharge and enrollment.
Results Mean discharge BNP level was 210  148 pg/ml. Twenty-eight patients were readmitted for decompensated HF
or suddenly died at a median time of 11 months from the time of discharge. Among various variables including
BNP measurements, clinical parameters and echocardiographic dimensions, a 6-month post-discharge BNP of
190 pg/ml was most closely associated with combined event in the Cox proportional hazards model (hazard
ratio 2.29; 95% confidence interval 1.42 to 3.56; p  0.0005), and had the best discriminatory power (area un-
der the receiver operating characteristic curve 0.91, sensitivity 96%; specificity 76%).
Conclusions Even in stable low-risk outpatients with NICM at 6 months after hospital discharge for decompensated HF, BNP
assessment predicts a long-term risk of redecompensation. (J Am Coll Cardiol 2008;51:2329–35) © 2008 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.085o
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lecompensated heart failure (HF) is a critical complication
f nonischemic dilated cardiomyopathy (NICM). Outcome
n those patients hospitalized for decompensated HF is
See page 2336
ften poor, and may include readmission for subsequent HF
r sudden death (1–3). A simple biomarker as a prognostic
redictor, thus, has been sought.
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007, accepted November 28, 2007.B-type natriuretic peptide (BNP) is secreted from the
verloaded left ventricle (LV), and the circulating levels
dversely increase in accordance with the degree of LV
all stretch (4,5). Plasma BNP levels have proven utility
n many settings, including improving the diagnostic
valuation of acute dyspnea (6,7) as well as the prognostic
valuation of HF patients on both hospital admission and
ischarge (8 –10). However, the clinical utility of BNP
ssay in stable outpatients after decompensated HF has
een poorly investigated. We hypothesized that the
rognostic utility of BNP assay would extend to this
utpatient setting, albeit with lower cutoff points for
igh- and low-risk statuses.
Here, we examined the relation of BNP assay with
ong-term outcome in stable outpatients with NICM after
ecompensated HF.
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Study population. Informed
consent was obtained from all
patients for participation in the
study in accordance with the pro-
tocol, which was approved by the
committee on human investiga-
tion at our institution. Consecu-
tive outpatients with NICM who
were clinically stable in New York
Heart Association (NYHA) func-
tional class 1 to 2 for at least 6
months after hospital discharge
for decompensated HF were
enrolled.
Admission for decompensated
HF was determined by adverse
cardiac symptoms (NYHA func-
tional class 3 to 4), physical find-
ings (rales and/or S3 gallop), and
evidence of pulmonary congestion
or pleural effusion on chest X-ray.
Nonischemic dilated cardiomyop-
athy was diagnosed according to
ardiac information during the hospital course including intact
oronary arteries on coronary angiography and LV systolic
ysfunction (left ventricular ejection fraction [LVEF] of
40%, LV diffuse wall motion abnormality) with a dilated
onhypertrophic LV (left ventricular end-diastolic dimension
LVDd] of 5.5 cm, posterior wall and interventricular
eptum end-diastolic thickness of 1.2 cm) on echocardiog-
aphy. Echocardiography and cardiac catheterization showed
oderate regurgitation of mitral and/or tricuspid valve with
he marked dilation of the ventricular cavities in almost all
atients, but did not show findings that indicate the existence
f primary valvular disease, such as prolapse, structural destruc-
ion, extreme calcification, or stenosis.
Discharge criteria were clinically compensated status as
ollows: NYHA functional class 3, no sign of rales or S3
allop, stable blood pressure (systolic blood pressure 90
m Hg), and improvement in renal failure (serum creati-
ine level1.5 mg/dl) as well as in chest X-ray findings and
F treatment including beta-blockers, angiotensin-
onverting enzyme inhibitor (ACEI), and angiotensin re-
eptor blocker (ARB), as recommended by the international
uideline (11).
To eliminate the possibility that acute ischemia could
recipitate HF decompensation, patients with coronary
rtery disease were excluded.
tudy protocol. Various parameters including BNP level
rom discharge to enrollment were correlated with outcome.
he attending physician was blinded to the BNP results
ntil the end of study.
Outpatient investigations including physical examination,
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
BNP  B-type natriuretic
peptide
CI  confidence interval
HF  heart failure
HR  hazard ratio
LADd  left atrial diastolic
dimension
LV  left ventricle/
ventricular
LVDd  left ventricular end-
diastolic dimension
LVEF  left ventricular
ejection fraction
NICM  nonischemic
dilated cardiomyopathy
NYHA  New York Heart
Associationlectrocardiogram recording, chest X-ray, and blood sample ceasurements were conducted every 3 months after dis-
harge. Entry patients were monitored for 18 months after
nrollment in the same institutes.
The major end point was sudden death or first readmis-
ion for decompensated HF, defined as hospitalization for
ecompensated HF. The cause of death was determined
ccording to autopsy in all those who died.
lasma BNP and echocardiographic measurements. Plasma
as immediately separated from the blood element by
entrifugation at 4°C for the measurement of BNP at
ischarge, 3 and 6 months after discharge using a specific
mmunoradiometric assay for human BNP (Shionoria,
saka, Japan). The minimum detectable quantity of human
NP is 2 pg/ml. The intra-assay and interassay coefficients
f variation were 5.2% and 6.1%, respectively.
In accordance with the recommendations of the American
ociety of Echocardiography, echocardiographic examination
as also performed at discharge and 6 months with a Hewlett
ackard Sonos 5500 machine (Andover, Massachusetts).
chocardiography was performed by experienced ultrasonog-
apher and repeated by the same operator wherever possible.
eft ventricular end-diastolic dimension at the level of the
itral valve leaflet tips and left atrial diastolic dimension
LADd) at the beginning of the QRS complex on the
lectrocardiography were measured by M-mode echocardiog-
aphy. Left ventricular ejection fraction was estimated by
impson’s method on 2-dimensional echocardiographs.
tatistical analysis. All values are expressed as mean 
tandard deviation. Differences between event-free patients
nd combined event patients at baseline were tested by using
he Student t test for continuous variables and the chi-
quare test with continuity equation for categoric variables.
ercentage change in BNP level from discharge to subse-
uent assay in each patient was expressed as follows: (BNP
evel at 3 or 6 months  BNP level at discharge) 
00/BNP level at discharge. The predictive values of clini-
al, echocardiographic, and biochemical variables for com-
ined event of all-cause death and readmission for decom-
ensated HF were examined with a Cox proportional
azards model. To compare the predictive values of the
arameters, receiver-operating characteristics and their area
nder the curve were constructed. The beat prognostic
utoff value for a combined event was defined as that which
ad the best compromise between sensitivity and specificity
or predicting readmission or sudden death. Failure curves
ere generated by the Kaplan-Meier method, and the
og-rank test was used to compare the incidence rate of a
ombined event or readmission alone among the BNP
anges.
The BNP levels at discharge, 3 and 6 months and
chocardiographic parameters at discharge and 6 months in
eadmitted patients or event-free patients were compared by
multivariate approach to repeated measures using the
eneral linear model, to allow correction for the correlation
f repeated observations over time. Probability was signifi-
ant at the value of p  0.05 level. Statistical analysis was
p
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June 17, 2008:2329–35 BNP in Outpatients With HFerformed with JMP 6.0 software for Windows (SAS
nstitute Inc., Cary, North Carolina).
esults
aseline patient characteristics. None of the 85 consecu-
ive NICM patients discharged with a clinically compen-
ated status was readmitted for decompensated HF within
he first 6 months. However, only 2 of those suddenly died
f a cardiac event. Finally, the remaining 83 outpatients
ho were clinically stable for 6 months after hospital
ischarge were enrolled in this study.
Entry patient characteristics are shown in Table 1. They
ere from age 25 to 84 years (mean age 56  20 years) and
linically stable in NYHA functional class 1 to 2 at least
ntil enrollment. Mean BNP levels were 210  148 pg/ml
t discharge, 182  158 pg/ml at 3 months, and 191  163
g/ml at 6 months. On echocardiography at discharge, all
atients had a dilated LV (mean LVDd 6.4  0.8 cm) and
ow LV systolic function (mean LVEF 31  8%), while
ean LVDd and LVEF at entry of 6.2  1.0 cm and 37 
aseline Characteristics
Table 1 Baseline Characteristics
Entire Po
(n 
Age, yrs 56
Gender, female, n (%) 24 (
Disease history, n (%)
Atrial fibrillation 30 (
Ventricular tachycardia 15 (
Hypertension 9 (
Diabetes 7 (
Medication use at enrollment
Digoxin, n (%) 14 (
Vasodilators, n (%) 7 (
Beta-blocker, n (%) 75 (
Carvedilol, mg/day 14
Metoprolol, mg/day 91
ACEIs, n (%) 70 (
ARBs, n (%) 16 (
Diuretics, n (%) 27 (
Amiodarone, n (%) 12 (
Permanent pacing, n (%)
Biventricular pacing 2 (
Cardiac defibrillator 2 (
BNP measurements, pg/ml
Plasma BNP level at discharge 210
Plasma BNP level at 3 months 182
Plasma BNP level at 6 months 191
Echocardiographic parameters
Left ventricular end-diastolic dimension at discharge, cm 6.4
Left ventricular ejection fraction at discharge, % 31
Left atrial diastolic dimension at discharge, cm 4.5
Left ventricular end-diastolic dimension at enrollment, cm 6.2
Left ventricular ejection fraction at enrollment, % 37
Left atrial diastolic dimension at enrollment, cm 4.5
Serum creatinine level at enrollment, mg/dl 1.1alues are mean  standard deviation. p values  event-free group versus combined event group.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BNP  B-type n0%, respectively. Other conditions identified in patients
ncluded atrial fibrillation (36%), ventricular tachycardia
19%), hypertension (11%), or diabetes (9%). Six patients
ere implanted with a permanent pacemaker for sick sinus
yndrome (n  2), atrial fibrillation (n  2), or intraven-
ricular dyssyncrony (n  2), and an implantable
ardioverter-defibrillator was inserted in 2 patients during
ospitalization, although 15 patients who had a low LVEF
f 36% with nonsustained or sustained ventricular tachy-
ardia were advised of the need for prophylactic implantable
ardioverter-defibrillator implantation to reduce the risk of
udden cardiac death (12). No patients required a mechan-
cal circulatory assist device for decompensated congestive
F. Beta-blocker together with ACEI or ARB was initi-
ted, and titrated in a clinically compensated status. How-
ver, withdrawal of the beta-blocker was performed in 8
atients early after hospital discharge, because of symptom-
tic hypotension or marked bradycardia (resting heart rate
f 40 beats/min). Among 75 patients with continuous
eta-blocker use, mean dosages of carvedilol and metoprolol
on Event-Free
(n  55)
Combined Event
(n  28) p Value
56 12 60 12 0.23
14 (25) 10 (34) 0.22
15 (27) 15 (54) 0.018
6 (11) 9 (32) 0.017
3 (5) 6 (21) 0.026
5 (10) 2 (7) 0.76
10 (20) 4 (14) 0.53
5 (10) 2 (7) 0.76
55 (100) 20 (71) 0.0001
16 5 8 5 0.0003
107 40 64 22 0.036
47 (85) 23 (79) 0.69
10 (20) 6 (21) 0.72
14 (25) 13 (38) 0.051
7 (13) 5 (17) 0.53
1 (2) 1 (3) 0.62
2 (4) 0 (0) 0.31
188 146 257 148 0.06
141 148 266 154 0.003
108 106 348 142 0.0001
6.5 0.8 6.5 0.8 0.41
31 9 31 7 0.43
4.3 0.8 4.8 0.9 0.0061
6.0 0.9 6.7 1.0 0.02
39 10 29 9 0.0005
4.1 0.8 5.4 0.9 0.0001
0.9 0.2 1.2 0.2 0.11pulati
83)
20
29)
36)
19)
11)
9)
18)
9)
90)
6
40
84)
20)
33)
15)
2)
2)
148
158
163
0.8
8
0.9
1.0
10
0.9
0.2atriuretic peptide.
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BNP in Outpatients With HF June 17, 2008:2329–35uring follow-up were 14 6 mg/day and 91 40 mg/day,
espectively. Finally, medical treatment at enrollment con-
isted of digoxin (18%), vasodilators (9%), beta-blockers
90%), ACEI (84%), ARB (20%), diuretics (33%), and
miodarone (15%).
utcome. Twenty-three patients were readmitted for
ecompensated HF, and 5 died suddenly of cardiac
vents (n  3) or noncardiac events (n  2), with a mean
r median time from discharge of 11.5  2.9 or 11 months,
ange 7 to 18 months.
omparison of clinical characteristics between sub-
roups. Clinical characteristics are compared between
vent-free patients and combined event patients in Table 1.
mong medications at enrollment, beta-blocker use and
osage of beta-blocker significantly differed between the 2
roups. Among disease history, atrial fibrillation, ventricular
achycardia, and hypertension showed significant differ-
nces. Age, gender, and serum creatinine level at enrollment
ad no significant difference. For BNP measurement,
lasma BNP levels at 3 and 6 months showed significant
ifferences between the 2 groups, whereas level at discharge
id not. Among echocardiographic parameters, only LVEF
nd LADd differed.
nivariate and Multivariate Cox Analyses of the Incidence of Death
Table 2 Univariate and Multivariate Cox Analyses of the Incide
Analysis for Contin
Variable HR 95% C
Univariate analysis
Age 1.0072 0.9879–1.
Gender (female)
Hypertension
Atrial fibrillation
Ventricular tachycardia
Beta-blocker use
Diuretic use
Echocardiographic parameters
Left ventricular end-diastolic dimension at
discharge
1.0045 0.7512–1.
Left ventricular ejection fraction at discharge 0.9997 0.9715–1.
Left atrial diastolic dimension at discharge 1.2541 0.9124–1.
Left ventricular end-diastolic dimension at
6 months
1.1829 0.9211–1.
Left ventricular ejection fraction at 6 months 0.9727 0.9476–0.
Left atrial diastolic dimension at 6 months 1.8127 1.3143–2.
BNP measurements
Plasma BNP level at discharge 1.0008 0.9993–1.
Plasma BNP level at 3 months 1.0013 0.9999–1.
Plasma BNP level at 6 months 1.0043 1.0026–1.
Percentage change in BNP level between discharge
and 3 months
1.0002 0.9979–1.
Percentage change in BNP level between discharge
and 6 months
1.0021 1.0000–1.
Multivariate analysis
Plasma BNP level at 6 months 1.0033 1.0011–1.
Percentage change in BNP level between discharge
and 6 months
1.0016 0.9988–1.
Left atrial diastolic dimension at 6 months 1.3918 0.9539–2.NP  B-type natriuretic peptide; CI  confidence interval; HF  heart failure; HR  hazard ratio.ox proportional hazards regression model for predictors
f readmission for HF. Associations among BNP mea-
urements as well as clinical and echocardiographic variables
or a combined event of death or readmission for decom-
ensated HF were examined using a Cox proportional
azards regression model (Table 2). Among clinical vari-
bles, no predictive variables were identified on univariate
nalysis. For echocardiography, LADd at 6 months was
ssociated with a combined event, notwithstanding the poor
redictability of LVEF. For BNP, plasma BNP level at 6
onths and percentage change in level between discharge
nd 6 months were predictive, whereas levels at discharge
nd 3 months were not. Area under the curve was higher for
NP at 6 months (0.91) than that for the percentage change
n BNP between discharge and 6 months (0.83) and LADd
t 6 months (0.86).
In multivariate analyses, which were conducted to include
ignificant variables on univariate analysis, only 6-month
ost-discharge BNP remained a significant predictor of a
ombined event, with the best cutoff value of 190 pg/ml at
his time having 96% sensitivity and 76% specificity (Fig. 1).
ix-month post-discharge BNP levels above this cutoff level
eadmission for HF
f Death or Readmission for HF
Variables Below Vs. Above Median Values
p Value Median Level HR 95% CI p Value
0.46 56 yrs 1.1895 0.7431–1.9246 0.47
1.0347 0.5886–2.0433 0.89
1.4902 0.8912–2.2819 0.18
1.2965 0.8885–2.0973 0.301
1.3012 0.9032–2.1693 0.17
1.6691 0.9056–2.5641 0.06
1.3551 0.8086–2.1936 0.24
0.98 6.4 cm 0.8356 0.5189–1.3516 0.48
0.99 30% 1.1629 0.7189–1.8729 0.54
0.18 4.5 cm 1.3054 0.8106–2.1164 0.28
0.21 6.0 cm 1.3866 0.8383–2.3598 0.22
0.03 36% 1.5019 0.9209–2.4641 0.11
0.0004 4.25 cm 2.0003 1.2436–3.2233 0.0046
0.24 180 pg/ml 1.2642 0.8051–1.9888 0.31
0.06 134 pg/ml 1.5097 0.9413–2.4212 0.09
0.0001 174 pg/ml 2.2679 1.4336–3.5863 0.0005
0.81 20.5% 1.4204 0.8863–2.2765 0.14
0.049 11.5% 2.0127 1.2729–3.1757 0.0026
0.0038 174 pg/ml 1.8427 1.1127–3.0426 0.0181
0.213 11.5% 1.6538 0.9991–2.7214 0.051
0.086 4.25 cm 1.5678 0.9486–2.5904 0.0792or R
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June 17, 2008:2329–35 BNP in Outpatients With HFtrongly related to a combined event (hazard ratio [HR] 2.3;
5% confidence interval [CI] 1.4 to 3.6; p  0.0005).
raded relation between 6-month post-discharge BNP
evel and readmission for HF. Kaplan-Meier curves con-
tructed according to 6-month post-discharge BNP values
Fig. 2A) showed that the risk of a combined event
ncreased in a stepwise fashion across increasing ranges of
-month post-discharge BNP, namely at 190 pg/ml, 190
o 380 pg/ml, and 380 pg/ml. Patients with a 6-month
ost-discharge BNP of 190 pg/ml had a better outcome
han those at 190 to 380 pg/ml (HR 5.0; 95% CI 2.5 to 9.9)
r 380 pg/ml (HR 11.5; 95% CI 4.5 to 29.2). Further,
aplan-Meier curves for incidence of readmission alone
Fig. 2B) showed the same pattern (HR 4.9 or 13.9; 95% CI
.5 to 9.8 or 4.5 to 30.1, respectively).
NP levels and echocardiographic dimensions from dis-
harge to 6 months post-discharge. Event-free patients
howed a sustained decrease in BNP level during the 6
onths after hospital discharge (mean  standard error of
he mean [SEM] of BNP level, 188  21 pg/ml at
ischarge, 141  21 pg/ml at 3 months, 108  15 pg/ml at
months; discharge vs. 3 months, p 0.0167; 3 months vs.
months, p  0.0094). In contrast, levels in patients
eadmitted for decompensated HF did not decrease during
ollow-up (256 28 pg/ml at discharge, 267 31 pg/ml at
months, 349  28 pg/ml at 6 months; discharge vs. 3
onths, p  0.79; 3 months vs. 6 months, p  0.0001)
Fig. 3A). Regarding changes in echocardiographic dimen-
ions, readmitted patients showed no decrease between
ischarge and 6 months in LVDd or LADd, or any
mprovement in LVEF (mean  SEM at discharge vs. 6
onths 6.5  0.1 cm vs. 6.7  0.2 cm, p  0.07; 4.8  0.2
m vs. 5.4  0.2 cm, p  0.0092; 31  1% vs. 29  2%,
 0.38, respectively), in contrast to event-free patients
Figure 1 ROC Curve for Cutoff Values
of BNP Levels at 6 Months Post-Discharge
A B-type natriuretic peptide (BNP) level of 190 pg/ml had the best compromise
between sensitivity (96%) and specificity (76%) for predicting readmission for
decompensated heart failure or sudden death. ROC  receiver-operating char-
acteristic. Area under curve  0.91.6.5  0.1 cm vs. 6.0  0.1 cm, p  0.0001; 4.3  0.1 cms. 4.1  0.1 cm, p  0.0064; 31  1% vs. 39  1%, p 
.0001, respectively) (Fig. 3B).
iscussion
ur data show that BNP levels provide important long-
erm prognostic information even in stable low-risk outpa-
ients after decompensated HF. The increased-risk thresh-
ld in healthy population screening is extremely low, on the
rder of 80 pg/ml as shown in the Framingham data (13). In
cute HF or acute coronary syndrome, when BNP levels are
levated, the cutoff point for increased risk increases to
bout 800 pg/ml as shown by the ADHERE (Acute
ecompensated Heart Failure National Registry) data (14).
s levels decline over time, however, the cutoff point on the
isk assessment curve at hospital discharge falls to about 500
g/ml (9,10). Our data extend this observation in time, to
how a cutoff point of about 200 pg/ml at 6 months after
ischarge (Fig. 1).
Entry patients in our study represent a low-risk group.
hey were clinically stable in NYHA functional class 1 to 2
or at least 6 months after discharge for decompensated HF,
lthough Krumholz et al. (1) indicated that almost one-half
f all patients admitted for decompensated HF are readmit-
ed within 6 months after discharge. Circulatory stabiliza-
ion on hospital discharge and socioeconomic status con-
ribute to this favorable clinical course (9,10,15). The 28%
Figure 2 Kaplan-Meier Analyses
Kaplan-Meier curves showing the incidence rate of readmission for decompen-
sated heart failure or sudden death (A) or of readmission alone (B) according
to 6-month post-discharge B-type natriuretic peptide (BNP) ranges. B-type natri-
uretic peptide ranges were 190 (the best cutoff level for predicting readmis-
sion or sudden death), 190 to 380, and 380 (its 2-fold level) pg/ml. p 
0.0001 (the log-rank test) versus a BNP range of 190 pg/ml.
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BNP in Outpatients With HF June 17, 2008:2329–35f patients in our study had a discharge BNP level of 100
g/ml, the optimal level in the exclusion of decompensated
F compared with only 10% in previous study (16), and our
opulation had an extremely low median BNP level of about
00 pg/ml at discharge (Table 1). In addition, our patients
eceived sufficient therapy for decompensated HF without
ocioeconomic restriction. With regard to the association
etween female gender and mortality, limited data exist in
atients with dilated cardiomyopathy (17), and the very
mall number of women in our population (Table 1) may
lso reflect that we selected a low-risk population.
Even this low-risk group had a long-term risk of read-
Figure 3 Changes in BNP Levels and Echocardiographic
Findings During a Clinically Compensated Status
Changes in B-type natriuretic peptide (BNP) at 3-month intervals after hospital
discharge (A) and in echocardiographic variables between discharge and 6
months (B). Solid or open circles indicate BNP levels, echocardiographic
dimensions (left ventricular end-diastolic dimension [LVDd]; left atrial diastolic
dimension [LADd]), and left ventricular ejection fraction (LVEF) in event-free
patients or patients readmitted for decompensated heart failure, respectively.
Values are mean  standard error of the mean. p values comparing changes
in BNP and echocardiographic variables between readmitted patients and
event-free patients are for repeated measures multivariate analysis of variance
over 6 months.ission for decompensated HF or sudden death, despite iF treatment including beta-blocker and ACEI, as recom-
ended by the international guideline (11). This discrep-
ncy can be explained by low maintenance dosages of and
ithdrawal of beta-blockers (18,19). Dosages of beta-
lockers in our population were extremely lower compared
ith those reached during recent multicenter trials (20,21),
nd patients who underwent the withdrawal of beta-
lockers were readmitted (Table 1). In addition, some
atients might be nonresponders to chronic beta-blocker
herapy (22). It is also possible that disease history of
rrhythmias might also affect outcome (23,24), although we
ould not confirm its prognostic role (Table 2).
Our data also show that 6-month post-discharge BNP is
losely associated with long-term outcome in this observa-
ional series, but BNP at 3 months as well as at discharge is
ot predictive of it (Table 2). In particular, the risk of
eadmission for decompensated HF adversely increased
long with increasing ranges of this level, although we were
nable to confirm an association with sudden death, owing
o the small number of patients who died (Fig. 2). High
lasma levels of BNP have been identified as major predic-
ors of progressive LV remodeling after acute myocardial
nfarction (25). In our study, readmitted patients, in contrast
o event-free patients, showed an increase in BNP levels
espite clinical stabilization and had no improvement in
chocardiographic parameters during the 6 months
ollow-up (Fig. 3). Increases in 6-month post-discharge
NP before clinical evidence of decompensation in part
eflect a poor reverse LV remodeling. Beta-blockers have
een shown to reverse LV remodeling (26) and to improve
linical outcome in patients with HF (20,21). Even in
linically stable low-risk group, higher-risk outpatients with
relatively high level of BNP, thus, may require an
ptimization of HF treatment including beta-blocker, im-
lying the potential role of BNP as a therapeutic guide even
n a stable outpatient setting.
Among several echocardiographic parameters, only
ADd at 6 months showed a significant association with
utcome (Table 2). The left atrium acts as a reservoir during
V systole (27), and LV diastolic dysfunction results in left
trial overload (28). Enlargement of the LADd may in part
eflect adverse LV diastolic dysfunction. However, this
ariable showed no predictive power in multivariate analysis,
ncluding BNP level. But previous reports in patients with
F have described an association between LV diastolic
ysfunction and outcome (29,30). Here, the involvement of
atients with tachycardia, atrial fibrillation, or permanent
acing meant that we were unable to confirm the predictive
ower in LV diastolic filling pattern.
Our data offer circumstantial, indirect support for the
etting of a target BNP level of 200 pg/ml in the
utpatient management of HF, as originally hypothesized
y the STARS-BNP (Plasma Brain Natriuretic Peptide-
uided Therapy to Improve Outcome in Heart Failure)
ulticenter study (31). The number of patients in our studys, however, relatively small, and additional prospective
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June 17, 2008:2329–35 BNP in Outpatients With HFulticenter studies will be necessary both to confirm our
bservation and to test a therapeutic utility of BNP assess-
ent in stable HF outpatients.
onclusions
o our knowledge, this study is the first to indicate that
ven in low-risk outpatients with nonischemic dilated car-
iomyopathy who have been asymptomatic for 6 months
fter hospital discharge for decompensated HF, BNP as-
essment identifies a long-term risk of readmission for
ecompensated HF. Our data confirm and extend the
linical utility of BNP assessment in patients with HF.
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